Kid Tested, FDA Approved: Examining Pediatric Drug Testing
Food and Drug Law Journal | Volume 72 | Number 4
When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA GalleryWhen the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA
Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Publications, Volume 72.4
When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA
Food and Drug Law Journal | Volume 72 | Number 4
The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls GalleryThe Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls
Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update November/December 2017
The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls
Update Magazine | September/October 2017
Brand Name Preemption: The New Frontier In Pharmaceutical Product Liability Litigation
Food and Drug Law Journal | Volume 72 | Number 4
The Value of FDA Pre-Submission Meetings & Enhancements under PDUFA VI
Update Magazine | November/December 2017
- Getting by with a Little Help from Their Friends: FDA Using External Experts to Enhance Biomarker Qualification and Enable Precision Gallery
Getting by with a Little Help from Their Friends: FDA Using External Experts to Enhance Biomarker Qualification and Enable Precision
Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Publications, Volume 72.4
Getting by with a Little Help from Their Friends: FDA Using External Experts to Enhance Biomarker Qualification and Enable Precision
Food and Drug Law Journal | Volume 72 | Number 4
Editorial or Ad? FTC’s Native Advertising Guidelines and Challenges for Industry GalleryEditorial or Ad? FTC’s Native Advertising Guidelines and Challenges for Industry
Drugs, Medical Devices, Biologics, Event, Food, Dietary Supplements, Cosmetics, General Webinars, On-demand Webinar, Tobacco Products
Editorial or Ad? FTC’s Native Advertising Guidelines and Challenges for Industry
Recorded November 29, 2017 | On-Demand Webinar
Development of Medical Devices: Best Practices for Safeguarding Your IP and FDA Rights
Recorded November 17, 2017 | On-Demand Webinar
Drug Quality Security Act Conference
November 15, 2017 I Washington, DC
Compounding the Off-Label Promotion Debate: How FDA Could Regulate the Promotion of Unapproved Drugs GalleryCompounding the Off-Label Promotion Debate: How FDA Could Regulate the Promotion of Unapproved Drugs
Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update September/October 2017
Compounding the Off-Label Promotion Debate: How FDA Could Regulate the Promotion of Unapproved Drugs
Update Magazine | September/October 2017
